Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery
Jupiter Neurosciences (NASDAQ: JUNS) has announced the launch of Nugevia™ PWR, a mitochondrial health supplement designed to enhance cellular energy, endurance, and recovery. The product leverages the company's proprietary JOTROL™ resveratrol-based platform technology and will be commercially available in Fall 2025.
The supplement combines JOTROL™, which showed a nine-fold increase in resveratrol bioavailability in Phase I trials, with NovaSOL® solubilized CoQ10. The product targets the longevity and wellness markets, projected to reach $8 trillion by 2030. PWR is designed as a two-capsule daily regimen and will join GLO in Jupiter's Nugevia™ product line.
The company positions PWR as a strategic revenue opportunity, aiming to generate high-margin returns to support its therapeutic development programs while addressing growing consumer demand for scientifically validated supplements.
Jupiter Neurosciences (NASDAQ: JUNS) ha annunciato il lancio di Nugevia™ PWR, un integratore per la salute mitocondriale progettato per migliorare l'energia cellulare, la resistenza e il recupero. Il prodotto sfrutta la tecnologia proprietaria JOTROL™, basata sul resveratrolo, e sarà disponibile commercialmente nell'autunno 2025.
L'integratore combina JOTROL™, che ha mostrato un aumento di nove volte della biodisponibilità del resveratrolo nelle prove di Fase I, con NovaSOL® CoQ10 solubilizzato. Il prodotto si rivolge ai mercati della longevità e del benessere, previsti raggiungere un valore di 8 trilioni di dollari entro il 2030. PWR è pensato come un regime quotidiano di due capsule e si unirà a GLO nella linea di prodotti Nugevia™ di Jupiter.
L'azienda considera PWR un'opportunità strategica di ricavo, con l'obiettivo di generare ritorni ad alto margine per sostenere i suoi programmi di sviluppo terapeutico, rispondendo al contempo alla crescente domanda dei consumatori di integratori convalidati scientificamente.
Jupiter Neurosciences (NASDAQ: JUNS) ha anunciado el lanzamiento de Nugevia™ PWR, un suplemento para la salud mitocondrial diseñado para mejorar la energía celular, la resistencia y la recuperación. El producto utiliza la tecnología patentada JOTROL™, basada en resveratrol, y estará disponible comercialmente en el otoño de 2025.
El suplemento combina JOTROL™, que mostró un aumento de nueve veces en la biodisponibilidad del resveratrol en los ensayos de Fase I, con CoQ10 solubilizado NovaSOL®. El producto está dirigido a los mercados de longevidad y bienestar, que se proyectan alcanzar un valor de 8 billones de dólares para 2030. PWR está diseñado como un régimen diario de dos cápsulas y se unirá a GLO en la línea de productos Nugevia™ de Jupiter.
La compañía posiciona PWR como una oportunidad estratégica de ingresos, con el objetivo de generar retornos de alto margen para apoyar sus programas de desarrollo terapéutico, mientras responde a la creciente demanda de los consumidores por suplementos validados científicamente.
Jupiter Neurosciences (NASDAQ: JUNS)는 세포 에너지, 지구력 및 회복력을 향상시키기 위해 설계된 미토콘드리아 건강 보조제인 Nugevia™ PWR의 출시를 발표했습니다. 이 제품은 회사의 독점적인 JOTROL™ 레스베라트롤 기반 플랫폼 기술을 활용하며, 2025년 가을에 상업적으로 출시될 예정입니다.
이 보조제는 1상 시험에서 레스베라트롤 생체이용률이 9배 증가한 JOTROL™과 NovaSOL® 용해형 CoQ10을 결합했습니다. 이 제품은 2030년까지 8조 달러에 달할 것으로 예상되는 장수 및 웰니스 시장을 목표로 합니다. PWR은 하루 두 캡슐 복용 체계로 설계되었으며, Jupiter의 Nugevia™ 제품군에 GLO와 함께 합류할 예정입니다.
회사는 PWR을 전략적 수익 기회로 자리매김하여, 치료 개발 프로그램을 지원하는 고수익을 창출하고 과학적으로 검증된 보조제에 대한 소비자 수요 증가에 대응하는 것을 목표로 하고 있습니다.
Jupiter Neurosciences (NASDAQ : JUNS) a annoncé le lancement de Nugevia™ PWR, un complément pour la santé mitochondriale conçu pour améliorer l'énergie cellulaire, l'endurance et la récupération. Ce produit utilise la technologie propriétaire JOTROL™ à base de resvératrol et sera disponible commercialement à l'automne 2025.
Le complément associe JOTROL™, qui a démontré une augmentation de neuf fois la biodisponibilité du resvératrol lors des essais de phase I, à la CoQ10 solubilisée NovaSOL®. Ce produit cible les marchés de la longévité et du bien-être, estimés à 8 000 milliards de dollars d'ici 2030. PWR est conçu pour être pris en deux capsules par jour et viendra compléter la gamme Nugevia™ de Jupiter, aux côtés de GLO.
L'entreprise positionne PWR comme une opportunité stratégique de revenus, visant à générer des marges élevées pour soutenir ses programmes de développement thérapeutique tout en répondant à la demande croissante des consommateurs pour des compléments scientifiquement validés.
Jupiter Neurosciences (NASDAQ: JUNS) hat die Einführung von Nugevia™ PWR angekündigt, einem Nahrungsergänzungsmittel zur mitochondrialen Gesundheit, das darauf ausgelegt ist, die zelluläre Energie, Ausdauer und Erholung zu verbessern. Das Produkt nutzt die firmeneigene JOTROL™-Technologie auf Resveratrol-Basis und wird im Herbst 2025 kommerziell erhältlich sein.
Das Supplement kombiniert JOTROL™, das in Phase-I-Studien eine neunfach erhöhte Resveratrol-Bioverfügbarkeit zeigte, mit NovaSOL® löslichem CoQ10. Das Produkt richtet sich an die Märkte für Langlebigkeit und Wellness, die bis 2030 voraussichtlich 8 Billionen US-Dollar erreichen werden. PWR ist als tägliche Einnahme von zwei Kapseln konzipiert und wird sich der GLO-Produktlinie in Jupiters Nugevia™-Portfolio anschließen.
Das Unternehmen sieht in PWR eine strategische Umsatzchance, mit dem Ziel, margenstarke Erträge zu generieren, um seine therapeutischen Entwicklungsprogramme zu unterstützen und gleichzeitig der wachsenden Verbrauchernachfrage nach wissenschaftlich validierten Nahrungsergänzungsmitteln gerecht zu werden.
- JOTROL demonstrated 9x increase in resveratrol bioavailability in Phase I trials
- Product targets longevity and wellness markets projected to reach $8 trillion by 2030
- Strategic expansion into high-margin consumer supplement market
- Leverages existing proprietary technology across both pharmaceutical and consumer verticals
- None.
PWR delivers science-driven cellular energy and recovery support as part of Jupiter’s expanding longevity supplement portfolio
Jupiter, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, is pleased to unveil Nugevia™ PWR, a daily mitochondrial health supplement scientifically formulated to support cellular energy, endurance, and recovery. PWR targets a rapidly expanding consumer demand for science-backed, clinically validated supplements, providing a high-margin growth opportunity within the longevity and wellness markets, projected to reach
Clinically Validated Cellular Fuel
Built on the same pharmaceutical-grade delivery platform behind Jupiter's CNS drug candidates, PWR pairs JOTROL™ with a curated blend of mitochondrial support ingredients to help optimize energy production, protect against oxidative stress, and enhance physical performance. The formulation was developed for adults seeking sustained strength, metabolic resilience, and recovery support grounded in clinical science.
"With PWR, we are tapping into the bioenergetic core of healthy aging," said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. "By leveraging our JOTROL™ platform beyond the clinic, we're offering a science-first approach to vitality and endurance that meets growing demand from consumers who want more than just a quick energy boost."
Advanced Mitochondrial Science for Endurance and Recovery
JOTROL™, which demonstrated a nine-fold increase in resveratrol bioavailability in Phase I trials, promotes mitochondrial biogenesis and energy metabolism through activation of longevity pathways. In PWR, JOTROL™ is combined with NovaSOL® solubilized CoQ10, a highly bioavailable antioxidant proven to enhance mitochondrial energy production and muscle function. Together, these ingredients create a powerful synergy—boosting both the quantity and quality of mitochondria, resulting in improved energy, endurance, and muscle recovery.
Taken together, these ingredients work in synergy to:
- Boost mitochondrial energy output
- Reduce exercise-related oxidative stress
- Support muscle recovery and stamina
- Promote sustained physical and mental performance
A Strategic Growth Catalyst
PWR reinforces Jupiter's strategy of monetizing its proprietary science across both pharmaceutical and consumer verticals. The supplement joins GLO in the broader Nugevia™ rollout, which the Company expects to serve as a high-margin revenue driver supporting therapeutic development.
"Each product in the Nugevia line represents both a scientific achievement and a strategic revenue opportunity," added Rosén. "With PWR, we're providing a differentiated option in the crowded energy space—one that delivers long-term benefits, not just a short-term boost."
Nugevia PWR is designed as a two-capsule-per-day regimen for optimal compliance and absorption.
A digital press kit, including high-resolution product imagery and key brand information, is available at https://ir.jupiterneurosciences.com/.
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia™ product line. Both efforts are powered by JOTROL™, Jupiter’s proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company’s prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson’s disease, includeing indications such as Alzheimer’s Disease, Mucopolysaccharidoses Type I, Friedreich’s Ataxia, and MELAS. More information may be found on the Company’s website www.jupiterneurosciences.com.
About JOTROL
Resveratrol is one of the world’s most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication.
Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL™ achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer’s Disease trial, and Yui et al., Friedreich’s Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL™ trials, were published in the Journal of Alzheimer’s Disease and AAPS Open in February 2022. JUNS is now advancing JOTROL™ toward a Phase IIa trial in Parkinson’s Disease.
In addition to its therapeutic applications, JOTROL™ serves as the foundation for Jupiter’s Nugevia™ consumer supplement line. By leveraging the same clinically validated delivery technology, Nugevia™ introduces pharmaceutical-grade bioavailability into the wellness space, offering targeted support for cognitive health, skin vitality, and cellular energy.
FORWARD-LOOKING STATEMENTS
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations, including the Company’s ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company’s final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company’s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
1-800-RED-CHIP (733-2447)
JUNS@redchip.com
FAQ
When will Jupiter Neurosciences (JUNS) launch Nugevia PWR?
What is the key technology behind Jupiter Neurosciences' Nugevia PWR supplement?
What is the recommended dosage for Jupiter Neurosciences' Nugevia PWR?
What market opportunity is Jupiter Neurosciences (JUNS) targeting with Nugevia PWR?
How does Nugevia PWR fit into Jupiter Neurosciences' business strategy?
